200,000+ products from a single source!
sales@angenechem.com
138154-39-9 | 6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-
CAS No: 138154-39-9 Catalog No: AG00183K MDL No:
Product Description
Catalog Number:
AG00183K
Chemical Name:
6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-
CAS Number:
138154-39-9
Molecular Formula:
C20H22N4O2
Molecular Weight:
350.4143
IUPAC Name:
10-[2-(diethylamino)ethylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
InChI:
InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
InChI Key:
CUNDRHORZHFPLY-UHFFFAOYSA-N
SMILES:
CCN(CCNc1ccc2c3c1c(=O)c1cc(O)ccc1n3cn2)CC
UNII:
MZ4Y5H4OAB
Properties
Complexity:
512
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
350.174g/mol
Formal Charge:
0
Heavy Atom Count:
26
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
350.422g/mol
Monoisotopic Mass:
350.174g/mol
Rotatable Bond Count:
6
Topological Polar Surface Area:
70.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.6
Literature
| Title | Journal |
|---|---|
| Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. | Drug metabolism and disposition: the biological fate of chemicals 20120901 |
| Influence of temperature and interactions with ligands on dissociation of dsDNA and ligand-dsDNA complexes of various types of binding. An electrochemical study. | Physical chemistry chemical physics : PCCP 20120314 |
| Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones. | Journal of medicinal chemistry 20111013 |
| Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis. | Cancer biology & therapy 20111001 |
| The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s. | Drug metabolism and disposition: the biological fate of chemicals 20110801 |
| Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110717 |
| Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. | Neoplasia (New York, N.Y.) 20110101 |
| Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. | Bioorganic & medicinal chemistry letters 20100501 |
| Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2. | Molecular pharmacology 20090501 |
| Thermoresponsive polymeric gel as a medium for examining interactions between dsDNA and an anticancer drug. | Analytical and bioanalytical chemistry 20081001 |
| Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. | Apoptosis : an international journal on programmed cell death 20071201 |
| Electroanalytical and spectroscopic procedures for examination of interactions between double stranded DNA and intercalating drugs. | Analytical and bioanalytical chemistry 20071101 |
| Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. | International journal of oncology 20071001 |
| Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay. | Journal of chemotherapy (Florence, Italy) 20071001 |
| C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. | Biochemical pharmacology 20070630 |
| The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. | International journal of oncology 20061201 |
| Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. | Journal of pharmaceutical and biomedical analysis 20050901 |
| Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20050301 |
| Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311. | PDA journal of pharmaceutical science and technology 20050101 |
| Similarity between enzymatic and electrochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinones. | Acta biochimica Polonica 20030101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.